Biohaven Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on the stock and has a $54.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Terence Flynn has given his Buy rating due to a combination of factors surrounding Biohaven Ltd.’s strategic initiatives and financial positioning. Despite receiving a complete response letter from the FDA regarding their NDA for Troriluzole, Biohaven is actively engaging with the FDA to address the issues and is focusing on strategic portfolio and cost optimization to ensure financial stability.
Biohaven’s emphasis on prioritizing clinical-stage programs, such as their lead extracellular degraders for IgA nephropathy and pivotal trials for Opakalim in adult focal epilepsy, demonstrates a clear path forward. Additionally, the company’s strong cash position of $408.2 million as of mid-2025 and their plan to significantly reduce R&D spending while maintaining a focus on high-priority projects are positive indicators for future growth. The anticipated data release for Opakalim in major depressive disorder later this year is also seen as a potential catalyst for the stock.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $15.00 price target.